Chinese biotechnology start-up Juventas announced on Tuesday that it has raised RMB100 million (US$14.51 million) in a series A+ round of financing led by Nasdaq-listed pharmaceutical firm CASI Pharmaceuticals.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?